0000950170-24-099980.txt : 20240822 0000950170-24-099980.hdr.sgml : 20240822 20240822192337 ACCESSION NUMBER: 0000950170-24-099980 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240821 FILED AS OF DATE: 20240822 DATE AS OF CHANGE: 20240822 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SINGLETON J MATTHEW CENTRAL INDEX KEY: 0001243514 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37355 FILM NUMBER: 241233185 MAIL ADDRESS: STREET 1: 286 STANWICH ROAD CITY: GREENWICH STATE: CT ZIP: 06830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viking Therapeutics, Inc. CENTRAL INDEX KEY: 0001607678 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461073877 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-704-4660 MAIL ADDRESS: STREET 1: 9920 PACIFIC HEIGHTS BLVD, SUITE 350 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-08-21 0001607678 Viking Therapeutics, Inc. VKTX 0001243514 SINGLETON J MATTHEW C/O VIKING THERAPEUTICS, INC. 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 true false false false true Common Stock, par value $0.00001 per share 2024-08-21 4 M false 5700 1.19 A 15200 D Common Stock, par value $0.00001 per share 2024-08-21 4 S false 5700 69.7246 D 9500 D Stock Option (Right to Buy) 1.19 2024-08-21 4 M false 5700 0 D 2018-01-03 2027-01-03 Common Stock 5700 10300 D The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 16, 2024 by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.50 to $69.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Michael Morneau, as Attorney-in-Fact 2024-08-22